[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332811-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-332811-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-liquid-biopsies-by-oxford-nanopore-technologies-sequencing-of-cell-free-dna-review","Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA - Review","","Liquid biopsies, especially analysis of circulating cell-free DNA (cfDNA), are expected to transform cancer diagnostics and therapy monitoring. Existing cfDNA liquid biopsy methods face limitations such as fragment interruption and GC bias. Oxford Nanopore Technologies (ONT) is emerging as a promising solution due to long read lengths, fast read times, high throughput, and PCR-free capability. This review summarizes ONT-based cfDNA liquid biopsy feasibility and applications, highlighting multimodal biomarker detection for early screening, diagnosis, and treatment monitoring.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-liquid-biopsies-by-oxford-nanopore-technologies-sequencing-of-cell-free-dna-review/332811/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-liquid-biopsies-by-oxford-nanopore-technologies-sequencing-of-cell-free-dna-review/332811.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are liquid biopsies and cfDNA analysis important in cancer care?","Question",{"text":63,"@type":64},"Liquid biopsies enable noninvasive access to cancer-related molecular signals. cfDNA profiles can support detection, molecular subtyping, surveillance, and prognostication.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What limitations affect current cfDNA-based liquid biopsy methods?",{"text":68,"@type":64},"PCR-based and NGS-based workflows can introduce issues such as fragment interruption and GC bias, and may limit methylation information.",{"name":70,"@type":61,"acceptedAnswer":71},"How does Oxford Nanopore Technologies (ONT) address these limitations?",{"text":72,"@type":64},"ONT provides long reads, fast read times, high throughput, and PCR-free sequencing, which supports resolving constraints seen in earlier cfDNA approaches and enables promising cancer research applications.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},332811,1790787739,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Si et al. Molecular Cancer (2024) 23:265 [https://doi.org/10.1186/s12943-024-02178-6](https://doi.org/10.1186/s12943-024-02178-6)  \nMolecular Cancer  \n REVIEW Open Access  \nCancer liquid biopsies by Oxford Nanopore   Technologies sequencing of cell-free DNA:  \nfrom basic research to clinical applications  \nHua-Qi Si 1,2†, Peng Wang3†, Fei Long1,2, Wei Zhong1,2, Yuan-Dong Meng4, Yuan Rong2*, Xiang-Yu Meng4* and Fu-Bing Wang1,2,5*  \nAbstract  \nLiquid biopsies, in particular, analysis of cell-free DNA, are expected to revolutionize the current landscape of cancer diagnostics and treatment. However, the existing methods for cfDNA-based liquid biopsies for cancer have certain limitations, such as fragment interruption and GC bias, which are likely to be resolved by the emerging Oxford Nanopore Technologies (ONT), characterized by long read-length, fast read-times, high throughput, and polymerase chain reaction-free. In this review, we summarized the current literatures regarding the feasibility and applications of cfDNAbased liquid biopsies using ONT for cancer management, a possible game-changer that we believe is promising in detecting multimodal biomarkers and can be applied in a wide range of oncology utilities including early screening, diagnosis, and treatment monitoring.  \nKeywords Oxford Nanopore Technologies, Cell-free DNA, Oncology, Liquid biopsies, Diagnosis, Personalized medicine  \n†Hua-Qi Si and Peng Wang contributed equally to this work.  \n*Correspondence:  \nYuan Rong [rongyuan323@whu.edu.cn](rongyuan323@whu.edu.cn)[ ](rongyuan323@whu.edu.cn)Xiang-Yu Meng [mengxy_whu@163.com](mengxy_whu@163.com)[ ](mengxy_whu@163.com)Fu-Bing Wang [wfb20042002@sina.com](wfb20042002@sina.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/.)[.](http://creativecommons.org/licenses/by-nc-nd/4.0/.)  \nSi etal. Molecular Cancer (2024) 23:265 Page 2 of 15  \nGraphical abstract  \nBackground  \nCancer imposes a significant impact on human health worldwide, with approximately 10 million people dying from cancer each year [1]. Although tissue biopsy is the gold standard for cancer diagnosis [2], it is limited by constraints on invasive procedures, poor patient compliance, and sampling frequency [2, 3]. CfDNA, a crucial component of liquid biopsy biomarkers, has emerged asa promising noninvasive alternative to tissue biopsy in cancer diagnosis and prognosis prediction [4]. CfDNA fragments are shed into body fluids by dying cells during apoptosis, necrosis, or secretion [5]. The fragments exhibit a wide size distribution, ranging from 20 bp to over 1 kb, with a notable peak at 166 bp. They predominantly circulate in a linear double-stranded configuration, also existing as linear single-stranded and circular forms [5, 6]. In addition, the half-life is variable ranging from 15 min to several hours [7]. Of note, the pool of cfDNA molecules contains ric","cbCaiofjWThVY6ZQ","https://ap.wps.com/l/cbCaiofjWThVY6ZQ","pdf",2282554,15,"English","# Abstract\n# Background\n## Clinical impact of cancer and limits of tissue biopsy\n## Biology of cfDNA: structure, fragmentomics, and half-life\n# Current technologies for cfDNA detection\n## PCR-based approaches\n## NGS-based approaches and limitations\n# Advances in liquid biopsy sequencing\n## PacBio and related constraints\n## Nanopore sequencing by ONT as fourth-generation sequencing","[{\"question\":\"Why are liquid biopsies and cfDNA analysis important in cancer care?\",\"answer\":\"Liquid biopsies enable noninvasive access to cancer-related molecular signals. cfDNA profiles can support detection, molecular subtyping, surveillance, and prognostication.\"},{\"question\":\"What limitations affect current cfDNA-based liquid biopsy methods?\",\"answer\":\"PCR-based and NGS-based workflows can introduce issues such as fragment interruption and GC bias, and may limit methylation information.\"},{\"question\":\"How does Oxford Nanopore Technologies (ONT) address these limitations?\",\"answer\":\"ONT provides long reads, fast read times, high throughput, and PCR-free sequencing, which supports resolving constraints seen in earlier cfDNA approaches and enables promising cancer research applications.\"}]","Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA - Review | PDF",1789999581,38]